Cyfuse Biomedical K.K. develops, manufactures, and sells regenerative medicine-related products in Japan, Europe, and the United States. The company offers the Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bone, blood vessels, and nerves; regenova, a 3D software that creates 3D data where spheroids shall be mounted; and S-PIKE that develops 3D-structures from cells. It also provides the Human 3D Mini-Liver, an in vitro MASH model that recapitulates human liver functions and predicts efficacy of drugs. Cyfuse Biomedical K.K. was incorporated in 2010 and is headquartered in Minato, Japan.
Frequently asked questions
What sector does Cyfuse Biomedical K.K. (4892) operate in?
Cyfuse Biomedical K.K. belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Cyfuse Biomedical K.K. (4892) current stock price?
As of the latest data, Cyfuse Biomedical K.K. stock price is ¥710, with a previous close of ¥668. Cyfuse Biomedical K.K. gained ¥42 in the last trading session, representing a 6.29% increase.
What is Cyfuse Biomedical K.K. (4892) current market capitalization?
Cyfuse Biomedical K.K. market cap is approximately 7.17 billion.
What is Cyfuse Biomedical K.K. (4892) Earnings Per Share (EPS)?
The trailing EPS is -¥81.
What is Cyfuse Biomedical K.K. (4892) EBITDA?
Cyfuse Biomedical K.K. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -195.42 million.
Does Cyfuse Biomedical K.K. (4892) pay dividends?
No. Cyfuse Biomedical K.K. does not pay a dividend.
What is Cyfuse Biomedical K.K. (4892) beta (volatility) score?
Cyfuse Biomedical K.K. has a beta of 1.439, suggesting it is more volatile than the market.
